2023
Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology
Qureshi H, Tabor J, Pickens K, Lei H, Vasandani S, Jalal M, Vetsa S, Elsamadicy A, Marianayagam N, Theriault B, Fulbright R, Qin R, Yan J, Jin L, O’Brien J, Morales-Valero S, Moliterno J. Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology. Journal Of Neuro-Oncology 2023, 164: 299-308. PMID: 37624530, PMCID: PMC10522517, DOI: 10.1007/s11060-023-04416-1.Peer-Reviewed Original ResearchBrain tumor patientsTumor patientsPostoperative outcomesFrailty indexSystematic reviewBrain tumorsPrimary intracranial tumorsMethodsSystematic literature reviewPrognostic valueVestibular schwannomaPostsurgical outcomesBenign tumorsIntracranial tumorsLesion etiologyTumor outcomeExclusion criteriaMalignant lesionsPRISMA guidelinesPatientsConclusionOur reviewTumor pathologyUnique etiologyTumor typesFrailtyNeurosurgical oncology
2020
Laser interstitial thermal therapy in neuro-oncology applications
Hong CS, Kundishora AJ, Elsamadicy AA, Chiang VL. Laser interstitial thermal therapy in neuro-oncology applications. Surgical Neurology International 2020, 11: 231. PMID: 32874734, PMCID: PMC7451173, DOI: 10.25259/sni_496_2019.Peer-Reviewed Original ResearchLaser interstitial thermal therapyRadiation necrosisInterstitial thermal therapyBrain tumorsNeurosurgical oncologyMultiple intracranial pathologiesRole of LITTStandard craniotomy approachesOptimal patient selectionMetastatic brain tumorsOpen surgical resectionInvasive surgical treatmentLesion-specific characteristicsSymptomatic peritumoral edemaNeuro-oncology applicationsMedical comorbiditiesBrain metastasesSurgical resectionSurgical treatmentPatient selectionRecurrent tumorsTumor characteristicsOpen surgeryCare treatmentCraniotomy approach
2018
Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. OncoImmunology 2018, 7: e1434464. PMID: 29872570, PMCID: PMC5980382, DOI: 10.1080/2162402x.2018.1434464.Peer-Reviewed Original ResearchChimeric antigen receptorMurine modelAntitumor efficacyFirst-line chemotherapyPhase I trialLong-term survivorsMajor side effectsB-cell malignanciesCAR immunotherapyCare temozolomideHost lymphodepletionLine chemotherapyAdoptive transferEffective immunotherapyI trialComplete regressionStandard treatmentIntracerebral tumorsSimilar efficacyTreatment strategiesT cellsGBM patientsBrain tumorsSide effectsOrthotopic glioma
2017
The Safety of available immunotherapy for the treatment of glioblastoma
Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH. The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opinion On Drug Safety 2017, 16: 277-287. PMID: 27989218, PMCID: PMC5404815, DOI: 10.1080/14740338.2017.1273898.Peer-Reviewed Original ResearchConceptsClinical trialsCurrent immunotherapiesCommon malignant primary brain tumorMalignant primary brain tumorAdoptive T-cell immunotherapyReviewed clinical trialsRole of immunotherapyImmune checkpoint blockadeMaximal surgical resectionOngoing clinical trialsPrimary brain tumorsT-cell immunotherapyTreatment of glioblastomaAdjuvant chemoradiationAvailable immunotherapiesCheckpoint blockadeCytokine therapySurgical resectionImmunotherapeutic approachesCell immunotherapyPatient survivalRecurrent glioblastomaVaccination strategiesSafety dataBrain tumors